Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 6,090,000 shares, a decline of 13.0% from the September 15th total of 7,000,000 shares. Based on an average daily trading volume, of 1,680,000 shares, the short-interest ratio is presently 3.6 days.

Adaptimmune Therapeutics Price Performance

Shares of ADAP opened at $0.88 on Wednesday. Adaptimmune Therapeutics has a 1 year low of $0.42 and a 1 year high of $2.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.09 and a quick ratio of 3.09. The stock has a 50 day simple moving average of $1.05 and a two-hundred day simple moving average of $1.10. The firm has a market cap of $217.21 million, a P/E ratio of -1.19 and a beta of 2.20.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported $0.27 earnings per share for the quarter. Adaptimmune Therapeutics had a negative net margin of 51.25% and a negative return on equity of 116.80%. The firm had revenue of $128.23 million during the quarter, compared to analyst estimates of $58.00 million. On average, analysts forecast that Adaptimmune Therapeutics will post -0.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on ADAP shares. HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Adaptimmune Therapeutics in a research report on Tuesday, August 13th. StockNews.com raised Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 13th.

Institutional Trading of Adaptimmune Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Columbia Advisory Partners LLC bought a new position in shares of Adaptimmune Therapeutics during the first quarter valued at about $25,000. JTC Employer Solutions Trustee Ltd purchased a new stake in Adaptimmune Therapeutics during the 1st quarter valued at about $41,000. Twin Focus Capital Partners LLC bought a new position in Adaptimmune Therapeutics during the 4th quarter worth approximately $44,000. Boulder Hill Capital Management LP purchased a new position in Adaptimmune Therapeutics in the 1st quarter worth approximately $143,000. Finally, Renaissance Technologies LLC increased its stake in Adaptimmune Therapeutics by 28.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after purchasing an additional 394,566 shares during the period. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.